Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 193


Short-term survivors in glioblastomas with oligodendroglioma component: a clinical study of 186 Chinese patients from a single institution.

Jiang H, Ren X, Wang J, Zhang Z, Jia W, Lin S.

J Neurooncol. 2014 Jan;116(2):395-404. doi: 10.1007/s11060-013-1311-3. Epub 2013 Nov 22.


Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma.

Laxton RC, Popov S, Doey L, Jury A, Bhangoo R, Gullan R, Chandler C, Brazil L, Sadler G, Beaney R, Sibtain N, King A, Bodi I, Jones C, Ashkan K, Al-Sarraj S.

Neuro Oncol. 2013 Dec;15(12):1635-43. doi: 10.1093/neuonc/not125. Epub 2013 Oct 24.


1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas.

Jiang H, Ren X, Cui X, Wang J, Jia W, Zhou Z, Lin S.

Neuro Oncol. 2013 Jun;15(6):775-82. doi: 10.1093/neuonc/not027. Epub 2013 Mar 13.


Glioblastoma with an oligodendroglioma component: distinct clinical behavior, genetic alterations, and outcome.

Wang Y, Li S, Chen L, You G, Bao Z, Yan W, Shi Z, Chen Y, Yao K, Zhang W, Kang C, Jiang T.

Neuro Oncol. 2012 Apr;14(4):518-25. doi: 10.1093/neuonc/nor232. Epub 2012 Feb 10.


Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.

Takahashi Y, Nakamura H, Makino K, Hide T, Muta D, Kamada H, Kuratsu J.

World J Surg Oncol. 2013 Oct 25;11:284. doi: 10.1186/1477-7819-11-284.


Differential molecular genetic analysis in glioblastoma multiforme of long- and short-term survivors: a clinical study in Chinese patients.

Zhang GB, Cui XL, Sui DL, Ren XH, Zhang Z, Wang ZC, Lin S.

J Neurooncol. 2013 Jun;113(2):251-8. doi: 10.1007/s11060-013-1102-x. Epub 2013 Mar 15.


Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.

Hartmann C, Hentschel B, Simon M, Westphal M, Schackert G, Tonn JC, Loeffler M, Reifenberger G, Pietsch T, von Deimling A, Weller M; German Glioma Network..

Clin Cancer Res. 2013 Sep 15;19(18):5146-57. doi: 10.1158/1078-0432.CCR-13-0017. Epub 2013 Aug 5.


Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.

Frenel JS, Leux C, Loussouarn D, Le Loupp AG, Leclair F, Aumont M, Mervoyer A, Martin S, Denis MG, Campone M.

J Neurooncol. 2013 Aug;114(1):85-91. doi: 10.1007/s11060-013-1152-0. Epub 2013 May 17.


Polysomy of chromosomes 1 and 19: an underestimated prognostic factor in oligodendroglial tumors.

Jiang H, Ren X, Zhang Z, Zeng W, Wang J, Lin S.

J Neurooncol. 2014 Oct;120(1):131-8. doi: 10.1007/s11060-014-1526-y. Epub 2014 Jul 10.


IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.

Clin Cancer Res. 2010 Mar 1;16(5):1597-604. doi: 10.1158/1078-0432.CCR-09-2902. Epub 2010 Feb 16.


Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis.

Figarella-Branger D, Mokhtari K, Colin C, Uro-Coste E, Jouvet A, Dehais C, Carpentier C, Villa C, Maurage CA, Eimer S, Polivka M, Vignaud JM, Laquerriere A, Sevestre H, Lechapt-Zalcman E, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Viennet G, Adam C, Loussouarn D, Michalak S, Rigau V, Heitzmann A, Vandenbos F, Forest F, Chiforeanu D, Tortel MC, Labrousse F, Chenard MP, Nguyen AT, Varlet P, Kemeny JL, Levillain PM, Cazals-Hatem D, Richard P, Delattre JY; POLA Network..

Brain Pathol. 2015 Jul;25(4):418-28. doi: 10.1111/bpa.12227. Epub 2014 Dec 31.


Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China.

Li S, Yan C, Huang L, Qiu X, Wang Z, Jiang T.

Neuro Oncol. 2012 Jan;14(1):109-16. doi: 10.1093/neuonc/nor185. Epub 2011 Oct 27.


Glioblastoma with oligodendroglial component represents a subgroup of glioblastoma with high prevalence of IDH1 mutation and association with younger age.

Ha SY, Kang SY, Do IG, Suh YL.

J Neurooncol. 2013 May;112(3):439-48. doi: 10.1007/s11060-013-1073-y. Epub 2013 Feb 15.


Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.

Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, Aldape KD, Jeuken JW, Wesseling P.

Mod Pathol. 2013 Jul;26(7):922-9. doi: 10.1038/modpathol.2012.166. Epub 2013 Feb 22.


Co-polysomy of chromosome 1q and 19p predicts worse prognosis in 1p/19q codeleted oligodendroglial tumors: FISH analysis of 148 consecutive cases.

Ren X, Jiang H, Cui X, Cui Y, Ma J, Jiang Z, Sui D, Lin S.

Neuro Oncol. 2013 Sep;15(9):1244-50. doi: 10.1093/neuonc/not092. Epub 2013 Jul 16.


[Analyses of IDH1 mutation and MGMT promoter methylation status for 5 cases of long-term survivors with glioblastoma].

Kamoshima Y, Motegi H, Terasaka S, Kobayashi H, Yamaguchi S, Murata J, Tanaka S, Houkin K.

No Shinkei Geka. 2012 Feb;40(2):129-35. Japanese.


Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers.

Minniti G, Arcella A, Scaringi C, Lanzetta G, Di Stefano D, Scarpino S, Pace A, Giangaspero F, Osti MF, Enrici RM.

J Neurooncol. 2014 Jan;116(2):275-82. doi: 10.1007/s11060-013-1288-y. Epub 2013 Oct 26.


A new der(1;7)(q10;p10) leading to a singular 1p loss in a case of glioblastoma with oligodendroglioma component.

Gadji M, Crous-Tsanaclis AM, Mathieu D, Mai S, Fortin D, Drouin R.

Neuropathology. 2014 Apr;34(2):170-8. doi: 10.1111/neup.12060. Epub 2013 Sep 30.


Glioblastoma with oligodendroglioma component (GBM-O): molecular genetic and clinical characteristics.

Appin CL, Gao J, Chisolm C, Torian M, Alexis D, Vincentelli C, Schniederjan MJ, Hadjipanayis C, Olson JJ, Hunter S, Hao C, Brat DJ.

Brain Pathol. 2013 Jul;23(4):454-61. doi: 10.1111/bpa.12018. Epub 2013 Jan 30.

Supplemental Content

Support Center